Cleerly Is Changing the Status Quo for Heart Disease DetectionCleerly Is Changing the Status Quo for Heart Disease Detection
The NY-based company has raised about $192 million in a series C round.
July 25, 2022
Cleerly has raised $192 million in a series C financing. With this round, the NY-based company has now raised a total of $248 million since inception.
Cleerly’s technology was born out of research from the Dalio Institute for Cardiovascular Imaging at the New York-Presbyterian Hospital and Weill Cornell Medicine and uses non-invasive coronary (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and FDA-cleared solutions.
The financing will enable Cleerly to expand its team as well as extend its commercial reach to broaden patient and physician access to its comprehensive technology.
Cleerly went on to say that it would invest in additional large-scale outcomes research to establish it as the standard of care supporting physicians through personalized evaluation and treatment of heart disease.
The oversubscribed funding round was led by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, and Fidelity Management and Research Company.
They are joined by additional investors spanning the healthcare, pharmaceutical and technology sectors, including Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, and Novartis. Cleerly’s existing investors also participated in the financing and include Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.
“At Cleerly, we are passionate about our mission to create a new standard of care for heart disease,” said James Min, MD, CEO and founder of Cleerly. “We are grateful for this round of financing that will further enable our work and believe it provides a resounding vote of confidence in our vision for the future of cardiovascular care. The status quo for heart health simply isn’t good enough – for patients, providers, or payors – and our proven approach to examining for early signs of heart disease through the build-up of arterial plaque promises to deliver the change we need right now.”
Min was a featured guest on episode 33 of Let’s Talk Medtech.
About the Author(s)
You May Also Like